Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Finch Therapeutics Group, Inc. (the “Company”) for the quarter ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the company, hereby certifies, pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to his or her knowledge:
Date: November 10, 2022 |
| By: | /s/ Mark Smith |
|
|
| Mark Smith, Ph.D. |
|
|
| Chief Executive Officer |
|
|
| (Principal Executive Officer) |
Date: November 10, 2022 |
| By: | /s/ Marc Blaustein |
|
|
| Marc Blaustein |
|
|
| Chief Operating Officer |
|
|
| (Principal Financial Officer and Principal Accounting Officer) |